SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 7, 2015) - Titan Pharmaceuticals, Inc. (
Pursuant to the terms of the warrants, the company elected to provide the opinion of counsel in lieu of filing a registration statement under the Securities Act covering the issuance and resale of the warrant shares. Section 3(a)(9) of the Securities Act provides an exemption from registration for a cashless exchange of the warrants for shares of common stock representing the fair market value of such warrants. Any warrant shares so issued will be eligible for immediate resale in the public market by holders not affiliated with Titan pursuant to the provisions of Rule 144 promulgated under the Securities Act.
About Titan Pharmaceuticals
Titan Pharmaceuticals Inc. (
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
CONTACT: Titan Pharmaceuticals, Inc.: Sunil Bhonsle President (650) 244-4990 Investors: Stephen Kilmer (647) 872-4849 skilmer@titanpharm.com Media: Susan Thomas (619) 540-9195 sthomas@titanpharm.com